Zoonotic infections arise from pathogens, including bacteria, viruses, parasites, or fungi, capable of crossing the species barrier between animals and humans. Originating in animals, these infections can be transmitted to humans through direct contact, consumption of contaminated food or water, or exposure in environments where animals and humans interact. Notable examples of zoonotic infections encompass influenza viruses, Ebola virus, Lyme disease, and Salmonella infections. The transmission dynamics of these diseases are influenced by factors such as ecological changes, human behaviors, and the adaptability of pathogens to diverse hosts. Zoonotic infections present considerable public health challenges due to their potential for rapid dissemination and the complexity of predicting and preventing their emergence. Effective management and prevention require surveillance, interdisciplinary collaboration between veterinary and human health professionals, and public awareness initiatives. A comprehensive understanding of the intricate dynamics of zoonotic infections is vital for addressing emerging threats, lessening their impact on human and animal health, and embracing a holistic One Health approach that recognizes the interconnections between human, animal, and environmental health.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States